




Society for  
Hematopathology/  
European Association  
for Haematopathology

## 2013 WORKSHOP

Progress in Acute Myeloid Leukemia,  
Myelodysplastic Syndromes and  
Acute Lymphoblastic Leukemia:

Classification and  
Molecular Pathogenesis

October 24–26, 2013

Submit cases to:  
<http://hematopathology 2013.org/>

Robert C. Hickey Auditorium • Floor 11, R. Lee Clark Clinic • 1515 Holcombe Boulevard  
The University of Texas MD Anderson Cancer Center • Houston, Texas

For more information, please call the Department of CME/Conference Management  
at 713-792-2223 or visit our website at [www.mdanderson.org/conferences](http://www.mdanderson.org/conferences).



**Society for Hematopathology**

**EUROPEAN ASSOCIATION  
FOR HAEMATOPATHOLOGY**



THE UNIVERSITY OF TEXAS

**MDAnderson  
Cancer Center**

Making Cancer History®

# Society for Hematopathology/European Association for Haematopathology 2013 Workshop

## Progress in Acute Myeloid Leukemia, Myelodysplastic Syndromes and Acute Lymphoblastic Leukemia: Classification and Molecular Pathogenesis

October 24–26, 2013

Robert C. Hickey Auditorium • Floor 11, R. Lee Clark Clinic • 1515 Holcombe Boulevard  
The University of Texas MD Anderson Cancer Center • Houston, Texas

### Program Overview

Acute myeloid leukemia (AML), myelodysplastic syndromes (MDS) and acute lymphoblastic leukemia (ALL), represent a heterogeneous group of malignancies that present unique challenges to pathologists. AML can also arise from MDS or myeloproliferative neoplasms and the genetic mechanisms of transformation are largely unknown. The advent of molecular diagnostics has heralded an explosion in new prognostic markers and many new entities were described in the recently published World Health Organization (WHO) classification of neoplasms of the hematopoietic system. Combined with sequencing and proteomic profiling, these technologies have helped identify new targets and signaling pathways, and may soon help to identify individual patients likely to benefit from specific therapies. Thus, this activity is designed to bring the spectrum of hematopoietic diseases to a forum for updating diagnostic criteria, pathophysiologic mechanisms and discussion. A unique aspect of this workshop is that we anticipate participation of expert hematopathologists, hematologists and oncologists from around the world.

### Program Co-Chairs

**Carlos E. Bueso–Ramos, MD, PhD**  
**L. Jeffrey Medeiros, MD**  
**Francisco Vega–Vazquez, MD, PhD**  
Department of Hematopathology  
MD Anderson

### Workshop Review Panel (Invited)

**Marie C. Béné, MD**  
**Brunangelo Falini, MD**  
**Kathy Foucar, MD**  
**Attilio Orazi, MD**  
**Anna Porwit, MD, PhD**  
**James Vardiman, MD**

### Program Committee

**Mark Routbort, MD, PhD**  
**Sa A. Wang, MD**  
**M. James You, MD, PhD**  
Department of Hematopathology  
MD Anderson

**Constance C. Tierney, CMP**  
Logistics Planner  
Department of CME/Conference Management  
MD Anderson

### Educational Objectives

**After attending the conference, participants should be able to**

- Appraise current WHO categories, and identify areas of diagnostic difficulty (*Knowledge, Competence, Performance*);
- Correlate the advances in molecular diagnostics and the molecular pathogenesis of these tumors (*Knowledge, Competence*);
- Connect new clinical approaches to treatment and monitoring of patients with AML, MDS, and ALL to hematopathology practice (*Knowledge, Competence, Performance, Patient Outcomes*).

### Target Audience

This conference is designed for physicians and other health professionals in hematopathology, pathology, hematology and oncology.

### Educational Methods

Lectures – Case Studies – Questions and Answers – Audience Response System

### Evaluation

A course evaluation form will provide participants with the opportunity to comment on the value of the program content to their practice decisions, performance improvement activities, or possible impact on patient health status. Participants will also have the opportunity to comment on any perceived commercial bias in the presentations as well as to identify future educational topics.

### Accreditation/Credit Designation

The University of Texas MD Anderson Cancer Center is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

The University of Texas MD Anderson Cancer Center designates this live activity for a maximum of 18.25 *AMA PRA Category 1 Credits™*. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

### CME Certificates and Attendance

#### Verification Certificates

Certificates awarding *AMA PRA Category 1 Credit™* or certificates documenting attendance will be distributed to participants when an individual departs the conference. To obtain a CME certificate, physicians must submit a completed evaluation questionnaire and a *CME Verification Form*.

Upon request, a record of attendance (certificate) will be provided on-site to other health care professionals for requesting credits in accordance with state nursing boards, specialty societies, or other professional associations.

### SAM Credits

The University of Texas MD Anderson Cancer Center Department of Hematopathology is approved by the American Board of Pathology (ABP) to provide Self-Assessment Module (SAM) credits. SAM credits are necessary to meet the ABP maintenance of certification requirements. SAM credits will be available for this conference.



## Types of Cases Sought for Workshop:

- Exemplary demonstration of all WHO categories of AML, MDS, and ALL using multiparameter correlations
- Therapy-related myeloid neoplasms
- Acute leukemias of ambiguous lineage and aggressive hematolymphoid tumors with unusual clinical, morphologic, immunophenotypic, or genetic features
- Progression and transformation with phenotypic changes and genetic lesions
- Interesting, illustrative or difficult cases of reactive myeloid and lymphoid proliferations mimicking aggressive neoplasms
- Tumors treated with new therapeutic agents

## Some questions to be addressed at the workshop:

- In the era of targeted therapy, what is the value of a classification system based on morphologic, immunophenotypic, and cytogenetic/molecular data?
- What should be the optimum immunophenotypic/molecular workup for cases of AML, MDS, and ALL at diagnosis, remission and relapse?
- How can we apply new target discovery to the classification of AML, MDS, and ALL?
- Are there potential new diagnostic entities that need to be considered?
- Can the diagnosis of AML with myelodysplasia-related changes be refined to reduce its current biologic heterogeneity?
- What is the optimum approach for defining lineage in cases of acute leukemia of ambiguous lineage?
- What are useful predictors of disease progression and poor prognosis in AML, MDS, and ALL?

## Case Requirements:

The workshop panel will select approximately 100 cases, and 50 will be presented at the meeting. **Early submissions are strongly encouraged.**

### For each case, we will request:

- One completed case submission form (available on the Case Submission & Workshop Case server website: <http://hematopathology2013.org/>)
- One CD containing critical images of the case in PowerPoint format
- 10 H & E stained slides and 10 unstained slides (biopsy or aspirate smears)
- Representative Wright-Giemsa stained slides or digital images of peripheral blood or bone marrow aspirate smears or fine needle aspirate material can be submitted where there is limited material, such as in bone marrow or blood cases.
- Critical immunostains flow cytometry immunophenotypic, cytogenetic and molecular data

### Send slides to:

Carlos E. Bueso-Ramos, MD, PhD  
Department of Hematopathology, Unit 72  
The University of Texas  
MD Anderson Cancer Center  
1515 Holcombe Boulevard  
Houston, TX 77030  
713-745-4798

**The deadline  
for case submissions  
is January 31, 2013.**

Notice of workshop acceptance  
will be sent by May 15, 2013.

## Wednesday, October 23, 2013

Pre-Symposium Program - Houston Marriott at the Texas Medical Center

4:00–7:00 p.m. Registration

7:00–8:00

**Independent Satellite Symposium (non-CME)  
Clinical Implications of Molecular Data in the  
Therapy of Lymphoblastic Leukemia/Lymphoma**  
Chair: Jorge E. Cortes, MD

## Thursday, October 24, 2013

MD Anderson Hickey Auditorium, Floor 11, R. Lee Clark Clinic

7:15–7:50 a.m. Registration/Continental Breakfast/Vendor Set-Up

7:50–8:00

**Welcome/Overview**  
Carlos E. Bueso-Ramos, MD, PhD

### AML and Related Neoplasms–Part I

8:00–9:20

**Session 1  
AML with Recurrent Genetic Abnormalities  
Part I–Abnormal Cytogenetics**  
Chairs: Kathy Foucar, MD and John Anastasi, MD

9:20–10:40

**Session 2  
AML with Recurrent Genetic Abnormalities  
Part II–Normal Cytogenetics**  
Chairs: Brunangelo Falini, MD and Pei Lin, MD

10:40–11:00

Break/Networking

11:00–12:20 p.m.

**Session 3  
AML with Myelodysplasia-related Changes**  
Chairs: James Vardiman, MD and  
Kaaren K. Reichard, MD

12:20–2:00

**Ventana Medical Systems, Inc. (Optional-non CME)  
A member of the Roche Group Satellite Symposium**

2:00–3:20

**Session 4  
Erythroleukemia and Acute Megakaryoblastic  
Leukemia and Mimics**  
Chairs: Robert P. Hasserjian, MD and Sa A. Wang, MD

3:20 – 4:40

**Session 5  
AML Secondary to Myeloproliferative  
Neoplasms (MPN) and Disease Progression in  
MDS and MDS/MPN**  
Chairs: Attilio Orazi, MD and Magdalena Czader, MD, PhD

6:30 p.m.

Dinner & Networking–Trevisio Restaurant

## Friday, October 25, 2013

7:00–7:30 a.m. Registration/Continental Breakfast

### AML and Related Neoplasms–Part II

7:30 – 8:50

#### **Session 6**

##### **Therapy-related Myeloid Neoplasms**

Chairs: Carlos E. Bueso–Ramos, MD, PhD and  
Curtis A. Hanson, MD

8:50–9:50

#### **Session 7**

##### **Extramedullary Manifestations of Myeloid Neoplasms**

Chairs: L. Jeffrey Medeiros, MD and  
Carla S. Wilson, MD, PhD

9:50–10:10

Break/Networking

10:10–11:30

#### **Session 8**

##### **Acute Leukemias of Ambiguous Lineage**

Chairs: Marie C. Béné, MD, and Anna Porwit, MD, PhD

11:30–1:00 p.m. Lunch/Networking

1:00–2:20

#### **Session 9**

##### **Myeloid and Lymphoid Neoplasms with Eosinophilia and Abnormalities of PDGFRA, PDGFRB or FGFR1**

Chairs: Francisco Vega–Vazquez, MD, PhD and  
Roberto N. Miranda, MD

2:30–5:10

##### **Scientific Mini-Symposium: Acute Leukemia in the Age of Genomics–based Medicine**

Chair: M. James You, MD, PhD

2:30–2:35

#### **Introduction**

M. James You, MD, PhD

2:35–3:10

##### **Genomics of Acute Myeloid Leukemia: Clinical Applications**

Timothy J. Ley, MD

3:10–3:45

##### **Acute Lymphoblastic Leukemia and Oncogenomics**

Charles Mullighan, MSc, MD

3:45–4:00

Break/Networking

4:00–4:35

##### **Unraveling the Molecular Pathophysiology of Myelodysplastic Syndromes**

Benjamin L. Ebert, MD, PhD

4:35–5:10

##### **Clinical Implications of Molecular Data in the Therapy of Acute Myeloid Leukemia**

Farhad Ravandi, MD

6:30 p.m.

##### **Dinner/Networking**–Marriott Houston Medical Center **Keynote Speaker**

Emil J Freireich, MD, DSc (Hon)

## Saturday, October 26, 2013

7:15 – 8:00 a.m. Registration/Continental Breakfast

### ALL and Related Neoplasms

8:00–9:20

#### **Session 10**

##### **B Lymphoblastic Leukemia/Lymphoma (Recurrent Translocations and NOS)**

Chairs: Jeffery Kutok, MD, PhD and  
Jeffrey L. Jorgensen, MD, PhD

9:20–10:40

#### **Session 11**

##### **T Lymphoblastic Leukemia/Lymphoma**

Chairs: Eric Hsi, MD and M. James You, MD, PhD

10:40 –11:00

Break/Networking

11:00–11:30

##### **SAMS Questions and Answers Review**

Francisco Vega–Vazquez, MD, PhD

11:30–11:40

##### **Closing Remarks and Adjourn**

L. Jeffrey Medeiros, MD

## Faculty

**John Anastasi, MD**  
University of Chicago  
Chicago, Illinois

**Marie C. Béné, MD**  
Faculte de Medecine de Nancy  
Vandoeuvre–les–Nancy, France

**Carlos E. Bueso–Ramos, MD, PhD**  
MD Anderson  
Houston, Texas

**Jorge E. Cortes, MD**  
MD Anderson  
Houston, Texas

**Magdalena Czader, MD, PhD**  
Indiana University School of Medicine  
Indianapolis, Indiana

**Benjamin L. Ebert, MD, PhD**  
Brigham and Women's Hospital  
Boston, Massachusetts

**Brunangelo Falini, MD**  
Institute Hematology at  
University of Perugia  
Perugia, Italy

**Kathy Foucar, MD**  
The University of New Mexico  
TriCore Reference Laboratory  
Albuquerque, New Mexico

**Emil J Freireich, MD**  
MD Anderson  
Houston, Texas

**Curtis A. Hanson, MD**  
Mayo Clinic  
Rochester, Minnesota

**Robert P. Hasserjian, MD**  
Massachusetts General Hospital  
Boston, Massachusetts

**Eric Hsi, MD**  
Cleveland Clinic  
Cleveland, Ohio

**Jeffrey L. Jorgensen, MD, PhD**  
MD Anderson  
Houston, Texas

**Jeffery Kutok, MD, PhD**  
Infinity Pharmaceuticals  
Cambridge, Massachusetts

**Timothy J. Ley, MD**  
Washington University Medical School  
St. Louis, Missouri

**Pei Lin, MD**  
MD Anderson  
Houston, Texas

**L. Jeffrey Medeiros, MD**  
MD Anderson  
Houston, Texas

**Roberto N. Miranda, MD**  
MD Anderson  
Houston, Texas

**Charles Mullighan, MSc, MD**  
St. Jude Children's Research Hospital  
Memphis, Tennessee

**Attilio Orazi, MD**  
Weill Cornell Medical College  
New York, New York

**Anna Porwit, MD, PhD**  
University of Toronto  
University Health Network  
Toronto General Hospital  
Toronto, Ontario, Canada

**Farhad Ravandi, MD**  
MD Anderson  
Houston, Texas

**Kaaren Reichard, MD**  
Mayo Clinic  
Rochester, Minnesota

**James Vardiman, MD**  
The University of Chicago  
Chicago, Illinois

**Francisco Vega–Vazquez, MD, PhD**  
MD Anderson  
Houston, Texas

**Sa A. Wang, MD**  
MD Anderson  
Houston, Texas

**Carla S. Wilson, MD, PhD**  
Tri Core Reference Labs–Hematopathology  
Albuquerque, New Mexico

**M. James You, MD, PhD**  
MD Anderson  
Houston, Texas

## Registration Information

On–site registration will be open from 4:00–7:00 p.m. on Wednesday, October 23, 2013 at the Houston Marriott at the Texas Medical Center, and at 7:15 a.m. on Thursday, October 24, 2013 at R. Lee Clark Clinic, Hickey Auditorium, Floor 11. The conference will begin at 7:50 a.m. on Thursday, October 24, and adjourn at 11:40 p.m. on Saturday, October 26. Advance registration is encouraged as space and materials are limited. Please see registration form for applicable fees.

**The deadline for advance registration is September 13, 2013.**

**There are three ways to register:**

- Mail to: CME/Conference Management–Unit 1381, The University of Texas MD Anderson Cancer Center, P.O. Box 301439, Houston, TX 77230–1439
- Fax to: 713–794–1724
- On–line at [www.mdanderson.org/conferences](http://www.mdanderson.org/conferences)

**We accept the following forms of payment:**

- Check (payable through U.S. banks only)
- Money Order
- Credit Cards (MasterCard, VISA, and American Express)
- Cash (on–site registration only)

A receipt and confirmation letter will be sent to you within ten working days of receipt of your fee.

The full conference registration fee includes the tuition, CD, breaks, lunches, and dinners.

### Refund/Cancellation Policy:

The registration fee, minus a \$50 administrative handling fee, is refundable if a written request is received on or before September 13, 2013. No refunds will be granted after that date. The request for a registration refund must include the tax identification number of the company or institution if registration was paid by a company or institution check.

The Department of CME/Conference Management reserves the right to cancel activities prior to the scheduled date, if low enrollment or other circumstances make it necessary. Each registrant will be notified by mail, e–mail, or the contact numbers as given on the registration form.

In case of activity cancellation, liability of the Department of CME/Conference Management is limited to the registration fee. CME/Conference Management will refund the full registration fee. The Department of CME/Conference Management reserves the right to limit the number of participants in a program and is not responsible for any expenses incurred by an individual whose registration is not confirmed and for whom space is not available.

For additional information, contact CME/Conference Management at 713–792–2223 or toll free at 866–849–5866.

## Special Assistance

Contact the Department of CME/Conference Management at 713-792-2223 or toll free at 866-849-5866 if you have any special dietary or ADA accommodation needs.

## Accommodations

- A block of rooms has been reserved for conference attendees at the **Houston Marriott at the Texas Medical Center**, 6580 Fannin Street, Houston, Texas.
- Early hotel reservation is suggested.
- The hotel phone number is 713-796-0080.
- When you make reservations be sure to mention the **Society of Hematopathology Conference** to be assured of receiving the special meeting rate of \$165.00 single or double occupancy. Please add 17% Texas state and local taxes. Reservations and deposits received after October 2, 2013 will be confirmed if space is available and at current hotel published guest room rates.

## Ground Transportation

- Houston is served by two airports, George Bush Intercontinental (IAH) and William P. Hobby (HOU).
- Taxicabs are available at an estimated cost of \$40-60, to or from George Bush Intercontinental Airport or William P. Hobby Airport.
- Super Shuttle operates a shuttle bus between George Bush Intercontinental Airport and the Houston Marriott at the Texas Medical Center, for \$23 one-way and \$42 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at [www.supershuttle.com](http://www.supershuttle.com).
- Super Shuttle operates a shuttle bus between William P. Hobby Airport and the Houston Marriott at the Texas Medical Center, for \$18 one-way and \$32 round-trip. For more information, call 713-523-8888 or toll-free at 800-258-3826 or on-line at [www.supershuttle.com](http://www.supershuttle.com).

Please let us know what specific topics, issues or questions you wish to see addressed or emphasized in this activity. Fax or e-mail CME/Conference Management. All responses will be forwarded to the Program Chairs for consideration.

The University of Texas MD Anderson Cancer Center has implemented a process whereby everyone who is in a position to control the content of an educational activity must disclose all relevant financial relationships with any commercial interest that could potentially affect the information presented. MD Anderson also requires that all faculty disclose any unlabeled use or investigational use (not yet approved for any purpose) of pharmaceutical and medical device products. Specific disclosure will be made to the participants prior to the educational activity.

Agendas are subject to change because we are always striving to improve the quality of your educational experience. MD Anderson may substitute faculty with comparable expertise on rare occasions necessitated by illness, scheduling conflicts, and so forth.

Photographing, audio taping and videotaping are prohibited.

## CONFERENCE REGISTRATION – 0620

### Society for Hematopathology/European Association for Haematopathology 2013 Workshop – October 24-26, 2013

|                                                                                                                                   |                             |                                                                    |                        |
|-----------------------------------------------------------------------------------------------------------------------------------|-----------------------------|--------------------------------------------------------------------|------------------------|
| Last Name                                                                                                                         | First                       | MI                                                                 | Highest Degree         |
| Department (include box no.)                                                                                                      |                             | Specialty                                                          |                        |
| Institution                                                                                                                       |                             | Physician <input type="checkbox"/> Yes <input type="checkbox"/> No |                        |
| Street                                                                                                                            | City                        | State/Foreign Country/Zip or Mail Code                             |                        |
| Daytime Phone (with area code)                                                                                                    | Cell Phone (with area code) |                                                                    | Fax (with area code)   |
| E-mail Address                                                                                                                    | Emergency Contact           |                                                                    | Phone (with area code) |
| Charge the following: <input type="checkbox"/> VISA <input type="checkbox"/> MasterCard <input type="checkbox"/> American Express |                             |                                                                    |                        |
| Credit Card Holder Name (First/Last)                                                                                              |                             | Credit Card Holder Billing Address & ZIP Code                      |                        |
| Credit Card Number or MD Anderson Interdepartmental Transfer (IDT) No.                                                            |                             | Expiration Date                                                    |                        |
| Authorized Signature REQUIRED for credit card or IDT                                                                              |                             | MD Anderson Employee ID No. (REQUIRED)                             |                        |
| IDT Approver Name (First/Last) please print                                                                                       |                             | IDT Approver E-mail                                                |                        |

**THIS IS NOT A SELF-MAILER-Address to:**  
Society for Hematopathology/European Association for  
Haematopathology 2013 Workshop

Department of CME/Conference Management—Unit 1381  
The University of Texas MD Anderson Cancer Center  
PO Box 301439, Houston, TX 77230-1439  
or fax to 713-794-1724

Make check or money order payable to:  
The University of Texas MD Anderson Cancer Center

## REGISTRATION FEES

### Members

- ☐ Postmarked before 9/13/13 .....\$600.00  
☐ Postmarked after 9/13/13 .....\$650.00

### Non-Members/MD Anderson Faculty

- ☐ Postmarked before 9/13/13 .....\$650.00  
☐ Postmarked after 9/13/13 .....\$700.00

### Trainees (including MD Anderson)

- ☐ Postmarked before 9/13/13 .....\$450.00  
☐ Postmarked after 9/13/13 .....\$500.00

The University of Texas MD Anderson Cancer Center  
CME/Conference Management – Unit 1381  
176700/30070620  
PO Box 301439  
Houston, Texas 77230-1439

---

Non-Profit Org.  
U.S. Postage  
PAID  
Houston, TX  
Permit No. 7052